X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Pharma Industry News - 11/Dec 15:12

Durable Response High With Obe-Cel in B-Cell Acute Lymphoblastic Leukemia

WEDNESDAY, Dec. 11, 2024 -- For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, results in a high...

Articles similaires

Sorry! Image not available at this time

Durable Response High With Obe-Cel in B-Cell Acute Lymphoblastic Leukemia

drugs.com - 11/Dec 15:12

WEDNESDAY, Dec. 11, 2024 -- For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an...

Sorry! Image not available at this time

ASH: Blinatumomab + Chemo Aids Survival in B-Cell Acute Lymphoblastic Leukemia

drugs.com - 12/Dec 16:12

THURSDAY, Dec. 12, 2024 -- For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for...

Sorry! Image not available at this time

ASH 2024: Preclinical study shows targeted drug strengthens the power of CAR T-cell therapy in two paediatric leukaemias

oncologynews.com.au - 20/Dec 18:24

A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib, a targeted cancer treatment, can...

Sorry! Image not available at this time

ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or refractory multiple myeloma

oncologynews.com.au - 19/Dec 17:46

Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median...

Sorry! Image not available at this time

Autologous Stem Cell Transplant Not Effective for MCL Patients, Study Shows

medindia.net - 13/Dec 08:12

Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with undetectable MRD.

Sorry! Image not available at this time

FDA Approves Ryoncil (remestemcel-L-rknd) Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft Versus Host Disease

drugs.com - 18/Dec 23:12

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

Sorry! Image not available at this time

FDA Approves Ryoncil (remestemcel-L-rknd) Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft Versus Host Disease

drugs.com - 18/Dec 23:12

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

Sorry! Image not available at this time

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

drugs.com - 19/Dec 01:12

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing...

Sorry! Image not available at this time

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

drugs.com - 19/Dec 01:12

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing...

Sorry! Image not available at this time

Neurocognitive Battery Feasible in 3-Year-Olds During Leukemia Treatment

drugs.com - 18/Dec 15:12

WEDNESDAY, Dec. 18, 2024 -- A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according...

Les derniers communiqués